|
19 Companies |
|
15 Products |
|
15 Products |
|
27 Mechanisms of Action |
|
0 Trials |
|
51 News |
|
- | zibotentan (ZD4054) / AstraZeneca
Trial completion, Enrollment change, Trial primary completion date: ZEBRA: Zibotentan Better Renal Scleroderma Outcome Study (clinicaltrials.gov) - Oct 31, 2017
P2, N=27, Completed, Sponsor: University College, London
Recruiting --> Completed | N=72 --> 27 | Trial primary completion date: Oct 2016 --> Oct 2017
- | Trial completion: Psychological Treatments for Scleroderma (clinicaltrials.gov) - Aug 8, 2017
P2, N=89, Completed, Sponsor: Johns Hopkins University
Recruiting --> Completed | N=72 --> 27 | Trial primary completion date: Oct 2016 --> Oct 2017 No longer recruiting --> Completed
- |||| cyclophosphamide / Generic mfg.
Trial completion: Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) (clinicaltrials.gov) - Feb 11, 2017
P2, N=142, Completed, Sponsor: Michael Roth
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Tracleer (bosentan) / J&J, Roche
Trial completion: ScS-REINBO: Effect of Bosentan in Scleroderma Renal Crisis (clinicaltrials.gov) - Jul 6, 2016
P2, N=16, Completed, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Active, not recruiting --> Completed
- cyclophosphamide / Generic mfg.
Trial completion, Enrollment change: SCOT Scleroderma Treatment Alternative Registry (STAR Registry) (clinicaltrials.gov) - May 19, 2016
P=N/A, N=19, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=45 --> 19
- ||| Trial completion, Enrollment change: Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients (clinicaltrials.gov) - May 3, 2016
P=N/A, N=602, Completed, Sponsor: Georgetown University
Active, not recruiting --> Completed | N=45 --> 19 Active, not recruiting --> Completed | N=400 --> 602
- Habeo Cell Therapy (ECCS-50) / Plus Therap
Enrollment change, Trial withdrawal: STAR: Scleroderma Treatment With Celution Processed ADRCs Registry (clinicaltrials.gov) - Mar 18, 2016
P=N/A, N=0, Withdrawn, Sponsor: Cytori Therapeutics
Active, not recruiting --> Completed | N=400 --> 602 N=500 --> 0 | Not yet recruiting --> Withdrawn
- | cyclophosphamide / Generic mfg.
Trial completion: Scleroderma Lung Disease (clinicaltrials.gov) - Feb 27, 2016
P3, N=158, Completed, Sponsor: The University of Texas Health Science Center, Houston
N=500 --> 0 | Not yet recruiting --> Withdrawn No longer recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough (clinicaltrials.gov) - Jan 11, 2016
P=N/A, N=7, Completed, Sponsor: Mayo Clinic
No longer recruiting --> Completed Recruiting --> Completed | N=12 --> 7 | Trial primary completion date: Dec 2016 --> Jun 2014
- Trial completion: The CARRA Registry (clinicaltrials.gov) - Nov 17, 2015
P=N/A, N=9587, Completed, Sponsor: Duke University
Recruiting --> Completed | N=12 --> 7 | Trial primary completion date: Dec 2016 --> Jun 2014 Enrolling by invitation --> Completed
- Tracleer (bosentan) / J&J, Roche
Trial primary completion date: ScS-REINBO: Effect of Bosentan in Scleroderma Renal Crisis (clinicaltrials.gov) - Oct 22, 2015
P2, N=16, Active, not recruiting, Sponsor: Assistance Publique - H
Enrolling by invitation --> Completed Trial primary completion date: Jul 2015 --> Oct 2015
- || Enrollment closed: Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients (clinicaltrials.gov) - Sep 25, 2015
P=N/A, N=400, Active, not recruiting, Sponsor: Georgetown University
Trial primary completion date: Jul 2015 --> Oct 2015 Recruiting --> Active, not recruiting
- Trial primary completion date: UVA1 Light for Scleroderma and Similar Conditions (clinicaltrials.gov) - Aug 14, 2015
P=N/A, N=23, Terminated, Sponsor: University of Michigan
Recruiting --> Active, not recruiting Trial primary completion date: May 2011 --> Jul 2003
- Trial primary completion date: UVA1 Light for Treatment of Scleroderma and Similar Conditions (clinicaltrials.gov) - Jul 10, 2015
P=N/A, N=27, Completed, Sponsor: University of Michigan
Trial primary completion date: May 2011 --> Jul 2003 Trial primary completion date: Mar 2008 --> Feb 2004
- | Dysport (abobotulinumtoxinA) / Ipsen, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment closed: Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome (clinicaltrials.gov) - Jun 15, 2015
P3, N=40, Active, not recruiting, Sponsor: Johns Hopkins University
Trial primary completion date: Mar 2008 --> Feb 2004 Recruiting --> Active, not recruiting
- Enrollment change: Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix (clinicaltrials.gov) - May 1, 2015
P1/2, N=33, Completed, Sponsor: University of Michigan
Recruiting --> Active, not recruiting N=50 --> 33
- | Tracleer (bosentan) / J&J, Roche
Enrollment closed: ScS-REINBO: Effect of Bosentan in Scleroderma Renal Crisis (clinicaltrials.gov) - Apr 30, 2015
P2, N=16, Active, not recruiting, Sponsor: Assistance Publique - H
N=50 --> 33 Recruiting --> Active, not recruiting
- | Trial completion: Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix (clinicaltrials.gov) - Apr 29, 2015
P1/2, N=33, Completed, Sponsor: University of Michigan
Recruiting --> Active, not recruiting Recruiting --> Completed
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Enrollment change: Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study (clinicaltrials.gov) - Apr 23, 2015
P3, N=0, Withdrawn, Sponsor: University of Alberta
Recruiting --> Completed N=20 --> 0
- || Enrollment status: The CARRA Registry (clinicaltrials.gov) - Apr 23, 2015
P=N/A, N=10000, Enrolling by invitation, Sponsor: Duke University
N=20 --> 0 Recruiting --> Enrolling by invitation
- cyclophosphamide / Generic mfg.
Enrollment closed, Trial primary completion date: SCOT Scleroderma Treatment Alternative Registry (STAR Registry) (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=45, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Mar 2016
- Trial primary completion date: Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=12, Recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Mar 2016 Trial primary completion date: Dec 2014 --> Dec 2016
- Enrollment change: UVA1 Light for Scleroderma and Similar Conditions (clinicaltrials.gov) - Feb 11, 2015
P=N/A, N=23, Terminated, Sponsor: University of Michigan
Trial primary completion date: Dec 2014 --> Dec 2016 N=50 --> 23
- | Dysport (abobotulinumtoxinA) / Ipsen, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment open, Trial initiation date: Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome (clinicaltrials.gov) - Jan 13, 2015
P3, N=40, Recruiting, Sponsor: Johns Hopkins University
N=50 --> 23 Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Jan 2015
- fluocinonide / Generic mfg.
Trial completion: Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea. (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=24, Completed, Sponsor: University of Texas Southwestern Medical Center
Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Jan 2015 Active, not recruiting --> Completed
- zibotentan (ZD4054) / AstraZeneca
Enrollment open, Trial primary completion date: ZEBRA: Zibotentan Better Renal Scleroderma Outcome Study (clinicaltrials.gov) - Nov 20, 2014
P2, N=72, Recruiting, Sponsor: University College, London
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Oct 2016
- | Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
Trial completion, Enrollment change: A Study of the Safety and Tolerability of MEDI-551 in Scleroderma (clinicaltrials.gov) - Nov 13, 2014
P1, N=50, Completed, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Oct 2016 Active, not recruiting --> Completed | N=27 --> 50
- || Trial primary completion date: Finger Hardness Measure in Scleroderma (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=60, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed | N=27 --> 50 Trial primary completion date: Sep 2013 --> Jan 2013
- ||| Trial completion, Trial primary completion date: Finger Hardness Measure in Scleroderma (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=60, Completed, Sponsor: Mayo Clinic
Trial primary completion date: Sep 2013 --> Jan 2013 Enrolling by invitation --> Completed | Trial primary completion date: Sep 2013 --> Jan 2013
- ||| Dysport (abobotulinumtoxinA) / Ipsen, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
New P3 trial: Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome (clinicaltrials.gov) - Jun 18, 2014
P3, N=40, Not yet recruiting, Sponsor: Johns Hopkins University
- Trial initiation date: A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma (clinicaltrials.gov) - Apr 15, 2014
P=N/A, N=29, Completed, Sponsor: Gilead Sciences
Enrolling by invitation --> Completed | Trial primary completion date: Sep 2013 --> Jan 2013 Initiation date: Mar 2013 --> Apr 2013
- | Trial completion: A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma (clinicaltrials.gov) - Apr 15, 2014
P=N/A, N=29, Completed, Sponsor: Gilead Sciences
Initiation date: Mar 2013 --> Apr 2013 Recruiting --> Completed
- | Trial completion: Oral Type I Collagen for Relieving Scleroderma (clinicaltrials.gov) - Feb 19, 2014
P2, N=168, Completed, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting --> Completed No longer recruiting --> Completed
- | sildenafil / Generic mfg.
Enrollment change: Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY (clinicaltrials.gov) - Jan 30, 2014
P3, N=84, Completed, Sponsor: University Hospital, Lille
No longer recruiting --> Completed N=120 --> 84
- | sildenafil / Generic mfg.
Trial completion: Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY (clinicaltrials.gov) - Jan 30, 2014
P3, N=84, Completed, Sponsor: University Hospital, Lille
N=120 --> 84 Recruiting --> Completed
- | zibotentan (ZD4054) / AstraZeneca
New P2 trial: ZEBRA: Zibotentan Better Renal Scleroderma Outcome Study (clinicaltrials.gov) - Jan 26, 2014
P2, N=72, Not yet recruiting, Sponsor: University College, London
- cyclophosphamide / Generic mfg.
Trial completion: Morbidity and Mortality Follow Up for the Scleroderma Lung Study (clinicaltrials.gov) - Jan 21, 2014
P=N/A, N=158, Completed, Sponsor: Duke University
Recruiting --> Completed Enrolling by invitation --> Completed
- mycophenolate mofetil / Generic mfg.
Enrollment change: Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement (clinicaltrials.gov) - May 5, 2013
P=N/A, N=7, Completed, Sponsor: University of California, San Francisco
Enrolling by invitation --> Completed N=10 --> 7
- cyclophosphamide / Generic mfg.
Enrollment closed: Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) (clinicaltrials.gov) - Apr 19, 2013
P2, N=142, Active, not recruiting, Sponsor: Philip Clements
N=10 --> 7 Recruiting --> Active, not recruiting
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change: Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma (clinicaltrials.gov) - Apr 3, 2013
P2, N=19, Completed, Sponsor: Northwestern University
Recruiting --> Active, not recruiting N=60 --> 19
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion: Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma (clinicaltrials.gov) - Dec 13, 2012
P2, N=19, Completed, Sponsor: Northwestern University
N=60 --> 19 Active, not recruiting --> Completed
- |||| Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp
Trial completion: DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine (clinicaltrials.gov) - Oct 18, 2012
P2, N=148, Completed, Sponsor: United Therapeutics
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Tracleer (bosentan) / J&J, Roche
Enrollment open: ScS-REINBO: Effect of Bosentan in Scleroderma Renal Crisis (clinicaltrials.gov) - Sep 13, 2012
P2, N=15, Recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Suspended --> Recruiting
- cyclophosphamide / Generic mfg.
Enrollment change: High Dose Cyclophosphamide for Treatment of Scleroderma (clinicaltrials.gov) - Mar 28, 2012
P3, N=8, Completed, Sponsor: Johns Hopkins University
Suspended --> Recruiting N=30 --> 8
- cyclophosphamide / Generic mfg.
Trial completion: High Dose Cyclophosphamide for Treatment of Scleroderma (clinicaltrials.gov) - Mar 28, 2012
P3, N=8, Completed, Sponsor: Johns Hopkins University
N=30 --> 8 Active, not recruiting --> Completed
- imatinib / Generic mfg.
New P2 trial, IO biomarker: Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma (clinicaltrials.gov) - Feb 29, 2012
P2, N=10, Terminated, Sponsor: Lawson Health Research Institute
- | Saphnelo (anifrolumab) / AstraZeneca
Trial completion: A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma (clinicaltrials.gov) - Jan 8, 2012
P1, N=34, Completed, Sponsor: MedImmune LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
Enrollment closed: A Study of the Safety and Tolerability of MEDI-551 in Scleroderma (clinicaltrials.gov) - Jan 5, 2012
P1, N=27, Active, not recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial termination: UVA1 Light for Scleroderma and Similar Conditions (clinicaltrials.gov) - Oct 2, 2011
P=N/A, N=50, Terminated, Sponsor: University of Michigan
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; inactivity